GSA Capital Partners LLP Invests $230,000 in IQVIA Holdings Inc. (NYSE:IQV)

GSA Capital Partners LLP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 970 shares of the medical research company’s stock, valued at approximately $230,000.

Several other hedge funds also recently bought and sold shares of the company. Apollon Wealth Management LLC boosted its stake in IQVIA by 9.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock worth $1,155,000 after purchasing an additional 427 shares during the period. Keystone Financial Services purchased a new position in shares of IQVIA in the third quarter worth $238,000. Versor Investments LP bought a new position in shares of IQVIA during the third quarter worth $1,328,000. Jag Capital Management LLC grew its stake in IQVIA by 2.1% during the third quarter. Jag Capital Management LLC now owns 12,431 shares of the medical research company’s stock valued at $2,946,000 after acquiring an additional 259 shares in the last quarter. Finally, GDS Wealth Management lifted its stake in IQVIA by 8.0% in the 3rd quarter. GDS Wealth Management now owns 54,893 shares of the medical research company’s stock worth $13,008,000 after purchasing an additional 4,056 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several research reports. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial reduced their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, BTIG Research lowered their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $256.50.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Stock Up 2.1 %

IQVIA stock opened at $201.82 on Monday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The firm has a market cap of $36.63 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.03 and a beta of 1.51. The business’s 50-day moving average price is $222.67 and its 200 day moving average price is $227.16. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.